NHI SVP granted 2,420 restricted shares

National Health Investors Inc reported that SVP, Legal Affairs Elizabeth Jackson Blankenship acquired 2,420 shares of common stock through a restricted stock grant at a stated price of $0.00 per share.

Accepted by SEC EDGAR 03/05/2026 - 04:52 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

National Health Investors Inc reported that SVP, Legal Affairs Elizabeth Jackson Blankenship acquired 2,420 shares of common stock through a restricted stock grant at a stated price of $0.00 per share.

The restricted shares vest in three equal annual installments on each anniversary of the March 3, 2026 grant date, beginning March 3, 2027, subject to her continued service through each vesting date.

Insider Trade Summary

Grant/Award: 2,420 shares

Grant/Award 1 txn

Insider Blankenship Elizabeth Jackson

Role SVP, Legal Affairs

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	2,420	$0.00	$0.00

Holdings After Transaction: Common Stock — 2,420 shares (Direct)

Holdings Before and After: Common Stock, 0 to 2,420 shares (Direct)

Footnotes (1)

1. F1. Represents a grant of restricted stock that vests in three equal annual installments on each anniversary of the grant date beginning March 3, 2027, subject to the reporting person's continued service through each vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did NHI report for Elizabeth Jackson Blankenship?

National Health Investors Inc reported a grant of 2,420 shares of common stock to SVP, Legal Affairs Elizabeth Jackson Blankenship as restricted stock, awarded at a stated price of $0.00 per share, according to a Form 4 insider transaction filing.

How many NHI shares were granted in this Form 4 filing?

The filing shows a grant of 2,420 shares of National Health Investors Inc common stock. These shares are in the form of restricted stock that vests over time, rather than an immediate unrestricted stock purchase on the open market.

What type of NHI security was involved in Elizabeth Jackson Blankenship’s award?

The transaction involved National Health Investors Inc common stock issued as restricted stock. This type of equity grant is typically subject to vesting conditions, meaning the shares become fully owned over time if service requirements are satisfied.

How does the vesting schedule work for the 2,420 restricted NHI shares?

The 2,420 restricted shares vest in three equal annual installments. Vesting occurs on each anniversary of the March 3, 2026 grant date, beginning March 3, 2027, provided Elizabeth Jackson Blankenship continues her service through the applicable vesting dates.

What was the reported price per share for the NHI restricted stock grant?

The Form 4 shows a transaction price of $0.00 per share for the restricted stock grant. This reflects an equity award from the company, rather than a cash purchase of National Health Investors Inc shares on the open market.

What role does Elizabeth Jackson Blankenship hold at National Health Investors Inc?

Elizabeth Jackson Blankenship is listed as SVP, Legal Affairs at National Health Investors Inc. The reported restricted stock grant of 2,420 shares reflects equity-based compensation associated with her senior executive position at the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Blankenship Elizabeth Jackson

(Last) (First) (Middle)

222 ROBERT ROSE DR

(Street)

MURFREESBORO TN 37129

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NATIONAL HEALTH INVESTORS INC [ NHI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Legal Affairs

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/03/2026		A		2,420(1)	A	$0	2,420	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a grant of restricted stock that vests in three equal annual installments on each anniversary of the grant date beginning March 3, 2027, subject to the reporting person's continued service through each vesting date.

	/s/ Kimberly V. Ouimet, by limited power of attorney	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.